Assessment of overall survival obtained from the real-world study of using the combination of palbociclib with aromatase inhibitors as a first-line treatment of HR+/HER2− metastatic breast cancer
Summary. Currently, the amount of data on the real-world effectiveness of palbociclib in combination with aromatase inhibitors (AI) versus AI monotherapy as first-line treatment for estrogen receptor–positive (ER+)/ human epidermal growth factor receptor 2–negative (HER2-) metastatic breast cancer (MBC) is insufficient. This retrospective analysis used data from the Flatiron Health Analytic Database. A total of 2888 patients (postmenopausal women and men) with HR+/HER2− MBC who initiated first-line treatment with palbociclib in combination with AI or AI monotherapy during February 3, 2015–March 31, 2020 were included in the study, and the follow-up period was ≥6 months. After stabilized inverse probability treatment weighting (sIPTW), median overall survival (OS) (95% confidence interval — CI) was significantly longer among palbociclib versus AI recipients (49.1 [45.2–57.7] versus 43.2 [37.6–48.0] months; hazard ratio, 0.76 [95% CI, 0.65–0.87]; P < 0.0001), and real-world progression-free survival (rPFS) (95% CI) was 19.3 (17.5–20.7) versus 13.9 (12.5–15.2) months, respectively (hazard ratio, 0.70 [95% CI, 0.62–0.78]; p<0.0001).
Leave a comment